Identification of TMEM217 as a novel prognostic biomarker and potential therapeutic target in acute myeloid leukemia

作     者：Yunying Yao Zhizhou Xi Min Wu Bo Jiao Jiaming Gao Donghe Li Xi Xie Pengfei Xu Jiaoyang Li Lei Yan Ruibao Ren Ping Liu Yunying Yao;Zhizhou Xia;Min Wu;Bo Jiao;Jiaming Gao;Donghe Li;Xi Xie;Pengfei Xu;Jiaoyang Li;Lei Yan;Ruibao Ren;Ping Liu

作者机构：Shanghai Institute of HematologyState Key Laboratory for Medical GenomicsNational Research Center for Translational MedicineCollaborative Innovation Center of HematologyRuijin Hospital affiliated with Shanghai Jiao Tong University School of MedicineShanghai 200025China International Center for Aging and CancerHainan Medical UniversityHaikouHainan 570102China 

出 版 物：《Genes & Diseases》 (基因与疾病（英文）)

年 卷 期：2024年第11卷第4期

页      面：90-93页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the Key Project of the National Natural Science Foundation of China(No.82230088 to R.R.) National Natural Science Foundation of China(No.81870112,82170147 to R.R.,No.81970134,82170111 to P.L.,No.82200200 to Z.X.) Shanghai Science and Technology Development Funds(China)(No.20Z11900200 to R.R.,No.18ZR1423600 to P.L) Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research(China)(No.2019CXJQ01 to R.R.) the Samuel Waxman Cancer Research Foundation(to R.R.) the Innovative Research Team of High-level Local Universities in Shanghai,China(to R.R.) the National Key Research and Development Program of China(No.2022YFC2705004 to P.L.) 

主　　题：acute myeloid leukemia 

摘      要：Despite remarkable advances in molecular and cell biology of acute myeloid leukemia(AML),AML patients still frequently relapse and have low 5-year overall survival(OS)rates.1 It is worth noting that a recent study from the registry or clinical trial compilation has reported an improvement in the OS of adult AML patients,especially those under 60 years of age.